GSK investigator going quietly to China jail; Type 2 diabetes expected to double among U.S. men;

@FiercePharma: ICYMI earlier: Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi. News | Follow @FiercePharma

@EricPFierce: Amgen recalls Aranesp from UK, Russia, 7 other countries after polyester particles found in syringes. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Valeant, Pershing Square: Bring on the SEC insider trading probe. More | Follow @CarlyHFierce

> British investigator Peter Humphrey and his wife Yu Yinzeng, convicted for the investigative work they did for GlaxoSmithKline ($GSK), will not appeal their prison sentences of two-and-a-half and two years, respectively. Story

> U.S. Sen. Dick Durban (D-IL) has sent a letter to Lake Forest, IL-based Hospira ($HSP), urging it not to relocate its headquarters to Europe in a so-called tax inversion deal. Story | More

> The FDA has warned consumers not to buy Ebola "cures" online because they are fraudulent. Release

Medical Device News

@FierceMedDev: Researchers explore 'shape-shifting' material for facial reconstruction. More | Follow @FierceMedDev

@StacyALawrence: ICYMI: Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients. Story | Follow @StacyALawrence

@VarunSaxena2: RT @FierceMedicalDev: We're looking for fierce women at the top of their game in #medtech. Learn more about how to nominate. More | Follow @VarunSaxena2

@EmilyWFierce: Senate democrats outlining a proposal to crack down on corporate tax inversions. Story via The Wall Street Journal | Follow @EmilyWFierce

> Foundation Medicine teams with MD Anderson for new trial of cancer Dx. News

> Top U.S. senator urges Hospira to abandon inversion plans. Story

> FDA launches pilot program for qualification of medical device development tools. Article

> Researchers explore 'shape-shifting' material for facial reconstruction. More

Biotech News

@FierceBiotech: RT @NickPaulTaylor: EuroBiotech: NeuroSearch convicted of stock manipulation, VBL IPO unravels, Prosensa plans EMA filing and more. Report | Follow @FierceBiotech

@DamianFierce: CF biotech ProQR, pursuing a $75M IPO, employs a "happiness manager." | Follow @DamianFierce

@EmilyMFierce: Glaxo quietly edges toward Ebola vaccine but clinical barriers remain. FierceVaccines story | Follow @EmilyMFierce

> Teva tries laquinimod in Huntington's after repeated MS woes. Story

> CF biotech ProQR shoots for a $75M IPO to challenge Vertex. Article

> Achillion shoulders its way into the hep C race with strong early data. More

And Finally... A new study predicts that 40% of U.S. adults born in the decade between 2000 and 2011 will develop Type 2 diabetes in their lifetime, which is double the rate for men and 50% higher for women born two decades earlier. Story

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.